Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 27;9(10):e111187.
doi: 10.1371/journal.pone.0111187. eCollection 2014.

MitProNet: A knowledgebase and analysis platform of proteome, interactome and diseases for mammalian mitochondria

Affiliations

MitProNet: A knowledgebase and analysis platform of proteome, interactome and diseases for mammalian mitochondria

Jiabin Wang et al. PLoS One. .

Abstract

Mitochondrion plays a central role in diverse biological processes in most eukaryotes, and its dysfunctions are critically involved in a large number of diseases and the aging process. A systematic identification of mitochondrial proteomes and characterization of functional linkages among mitochondrial proteins are fundamental in understanding the mechanisms underlying biological functions and human diseases associated with mitochondria. Here we present a database MitProNet which provides a comprehensive knowledgebase for mitochondrial proteome, interactome and human diseases. First an inventory of mammalian mitochondrial proteins was compiled by widely collecting proteomic datasets, and the proteins were classified by machine learning to achieve a high-confidence list of mitochondrial proteins. The current version of MitProNet covers 1124 high-confidence proteins, and the remainders were further classified as middle- or low-confidence. An organelle-specific network of functional linkages among mitochondrial proteins was then generated by integrating genomic features encoded by a wide range of datasets including genomic context, gene expression profiles, protein-protein interactions, functional similarity and metabolic pathways. The functional-linkage network should be a valuable resource for the study of biological functions of mitochondrial proteins and human mitochondrial diseases. Furthermore, we utilized the network to predict candidate genes for mitochondrial diseases using prioritization algorithms. All proteins, functional linkages and disease candidate genes in MitProNet were annotated according to the information collected from their original sources including GO, GEO, OMIM, KEGG, MIPS, HPRD and so on. MitProNet features a user-friendly graphic visualization interface to present functional analysis of linkage networks. As an up-to-date database and analysis platform, MitProNet should be particularly helpful in comprehensive studies of complicated biological mechanisms underlying mitochondrial functions and human mitochondrial diseases. MitProNet is freely accessible at http://bio.scu.edu.cn:8085/MitProNet.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. A flowchart depicting the work.
(A) Step 1: obtaining a mitochondrial proteins inventory utilizing machine learning classification. (B) Step 2: constructing the FLN by integrating 11 genomic features including protein-protein interaction, domain-domain interaction, shared domains, genomic context, genetic interaction, phenotypic semantic similarity, co-expression, GO semantic similarity, protein expression profiles, disease involvement and operon based on the Naïve bayes model. (C) Step 3: ranking the disease candidate genes utilizing the FLN and a network-based algorithm. The table on the right shows the ranking scores of the top 5 candidate genes for mitochondrial complex I deficiency.
Figure 2
Figure 2. Venn diagram of the four datasets: MitoCom (high-confidence), MitoCom (middle-confidence), MitoCarta and MitoPred.
Figure 3
Figure 3. ROC curves for evaluating the performances of various data sources using cross-validations.
(A) ROC curves and AUC of individual dataset and integrated dataset. The data sources are highlighted in different colors. (B) ROC curves and AUC of mitochondrial-specific (green) and genome-scale (blue) datasets. ID: Integrated datasets; ProP: Protein expression profiles; DDI: Domain-Domian Interaction; GI: Genetic Interaction; DI: Disease Involvement; PSS: Phenotypic Semantic Similarity; PheP: Phylogenetic Profiles; RS: Rosetta Stone; PPI: Protein-Protein Interaction; SD: Shared Domains; GOSS: GO Semantic Similarity; IGD: Integrated Genomic-scale Datasets; IMG: Integrated Mitochondrial-specific Datasets; ROC: receiver operating characteristic; AUC: area under ROC curves.
Figure 4
Figure 4. TP/FP ratios vs. LR cutoff, and corresponding sensitivity.
TP: True Positive; FP: False Positive. Sensitivity = TP/(TP+FN).
Figure 5
Figure 5. ROC curves for evaluating the performances of four networks on disease-gene prioritization.
(A) The ROC curve for FLN. (B) The ROC curve for FLNhm. (C) The ROC curve for PPI network. (D) The ROC curve for co-expression network. AAR: Average Adjacency Ranking; PRP: PageRank with Priors; KSM: K-Step Markov; HKDR: Heat Kernel Diffusion Ranking; FLN: Functional Linkage Network among high-confidence mitochondrial proteins; FLNhm: Functional Linkage Network among high-confidence and middle-confidence mitochondrial proteins; PPIN: Protein-Protein Interaction Network; CEN: Co-Expression Network.
Figure 6
Figure 6. Prioritization results for mitochondrial complex I deficiency.
(A) A hypothetical FLN of mitochondrial complex I deficiency. The FLN is comprising of known disease genes (highlighted in red) annotated in OMIM and predicted disease genes (highlighted in greed). The candidates are classified into three levels (high-confidence, middle-confidence and low-confidence) according to their ranking scores. (B) The functional linkage sub-network among the candidate NDUFS3 that has a top score on ranking algorithm for mitochondrial complex I deficiency.
Figure 7
Figure 7. System architecture and main contents of MitProNet.
MitProNet is composed of three sections including mitochondrial protein part lists, annotations of mitochondrial protein and disease information.
Figure 8
Figure 8. Web pages in MitProNet.
(A) A list page of mitochondrial proteins. The mitochondrial proteins can be listed according to proteomic datasets, confidence levels and organisms, respectively. (B) The outcome page for the query protein NDUFS7, an annotated disease gene for Leigh syndrome. The page provides a brief summary of the query protein, subcellular localization evidences and a FLN among the query protein. Moreover, the query protein is annotated according to the information collected from their original sources including GO, KEGG, MIPS and OMIM. (C) The prioritization results for Leigh syndrome. The result page includes a brief description for this phenotype, disease genes and a FLN among these genes. The disease genes are listed dividedly as the known genes and the candidates that are ordered by these ranking scores.

Similar articles

Cited by

References

    1. Chan DC (2006) Mitochondria: dynamic organelles in disease, aging, and development. Cell 125: 1241–1252. - PubMed
    1. Facecchia K, Fochesato LA, Ray SD, Stohs SJ, Pandey S (2011) Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies. J Toxicol 2011: 683–728. - PMC - PubMed
    1. Shenouda SM, Widlansky ME, Chen K, Xu G, Holbrook M, et al. (2011) Altered mitochondrial dynamics contributes to endothelial dysfunction in diabetes mellitus. Circulation 124: 444–453. - PMC - PubMed
    1. Traish AM, Abdallah B, Yu G (2011) Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease. Hormone Molecular Biology and Clinical Investigation 8: 431–444. - PubMed
    1. Johri A, Beal MF (2012) Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics 342: 619–630. - PMC - PubMed

Publication types